investorscraft@gmail.com

Intrinsic value of Medpace Holdings, Inc. (MEDP)

Previous Close$165.66
Intrinsic Value
Upside potential
Previous Close
$165.66

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh45.35 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %23.3NaN
Revenue, $1142NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m943NaN
Operating income, $m199NaN
EBITDA, $m236NaN
Interest expense (income), $mNaN
Earnings before tax, $m201NaN
Tax expense, $m20NaN
Net income, $m181NaN

BALANCE SHEET

Cash and short-term investments, $m461NaN
Total assets, $m1660NaN
Adjusted assets (=assets-cash), $m1199NaN
Average production assets, $m918NaN
Working capital, $m134NaN
Total debt, $m147NaN
Total liabilities, $m707NaN
Total equity, $m953NaN
Debt-to-equity ratio0.154NaN
Adjusted equity ratio0.424NaN

CASH FLOW

Net income, $m181NaN
Depreciation, amort., depletion, $m37NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m279NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-28NaN
Free cash flow, $m307NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m134
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount